



Temisis nominated for the Prix Galien MedStartUp

Plant Advanced Technologies PAT announces that Temisis, its subsidiary dedicated to the development of anti-inflammatory active compounds, is one of three finalists for the Prix Galien MedStartUp 2018. Laureates will be revealed during the ceremony of the Prix Galien that will take place in a prestigious place, the Museum of Natural History in New York on October 25th 2018.

Temisis is nominated thanks to its lead molecule, TEM1657, recognized as a disruptive solution in the treatment of psoriasis.



Organized by the Galien Foundation and Business France, the Prix Galien MedStartUp rewards the most promising start-ups in the biomedical sector, created from international partnerships between innovators from France, Israel and the USA.

“ We are very happy that our subsidiary is being recognized during this prestigious event that gathers each year the greatest pharmaceutical groups such as Roche, Sanofi or Pfizer. This confirms our ability to propose innovative products in the biomedical field.” commented Jean-Paul Fèvre, CEO of Plant Advanced Technologies.

[All about PAT on plantadvanced.com](http://plantadvanced.com)

About PAT:

PAT is specialized in identifying, optimizing and producing rare active compounds of plant origin designed for cosmetics, pharmaceuticals and agrochemistry. PAT's exclusive know-how is worldwide patented (PAT plant milking® et Target Binding®). PAT is listed on Euronext Growth™ of Euronext Paris (ISIN code: FR0010785790 – Mnemonic code: ALPAT).

About Temisis :

Temisis is a 100% subsidiary of PAT, dedicated to the development of anti-inflammatory active ingredients including TEM1657. This drug candidate, patented in 2016, demonstrates significant effects against psoriasis, by oral and local application, and to date without side effects. www.temisis.com

About prix Galien MedStartUp :

The global rendez-vous for Healthcare innovation. The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives. <https://medstartup.galienfoundation.org/>



For investors

invest@plantadvanced.com

For Press relations

communication@plantadvanced.com

Tel.: +33 (0)3 83 94 03 42

PAT is eligible to PEA (Equity Savings Plan) and PEA SME dispositions

Financial communication

Solène KENNIS / Jérôme GACOIN

Tel.: +33 (0)1 75 77 54 68

skennis@aelium.fr

